1Weyer. Dificiency in AIR predict IGT and Type 2 diabetes. Diabetes Care, 2001,24 : 89-94.
2Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes, 1995,44: 1386-1391.
3Bruce DG, Chisholm DJ, Leonare H, et al. Physiological importance of deficiency in early prandial insulin secretion in non-in-sulin-dependent diabetes. Diabetes, 1988,37: 736-743.
4Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes, 1999,48: 99-105.
5Ilkova H, glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
6Walton C, Godsland IF, Proudler AJ, et al. Effect of body mass index and fat distribution on insulin sensitivity, secretion, and clearance in nonobese healthy men. J Clin Endocrinol Metab,1992,75: 170-175.
7Guillausseau PJ. Compliance and optimization of oral antidiabetie therapy: a longitudial study. Presse Med, 2004, 33: 156-160.
8Lu CH, Chang CC, Chuang LM, et al. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Diabetes Obes Metab, 2006, 8: 184-191.
9Satoh J, Takahashi K, Takizawa Y, et al. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract, 2005, 70 : 291-297.
10Kimoto K, Suzuki K, Kizaki T, et al. Gliclazide pro- tects pancreatic beta-cells from damage by hydrogen per- oxide. Biochem Biophys Res Commun, 2003, 303: 112-119.
